Indian healthtech entered 2025 after a clear capital reset. Investor selectivity sharpened in 2025, with Indian healthtech raising approximately $828 million in the first half of the year, while full-year totals vary by source depending on classification. Within this, digital therapeutics remains a relatively small slice: the domestic DTx market itself is estimated at ~$260 million in 2025, underscoring that investor interest has narrowed to fewer, more defensible models rather than broad, narrative-led bets. Capital did not exit healthtech; it became selective.
This selectivity exposed the gap between adoption narratives and economic reality. Consumer-facing health platforms reached tens of millions of users, yet revenues largely remained in the low hundreds of crores. Lifetime capital raised frequently exceeded 5-6x annual revenue, and in some cases >7x, highlighting the difficulty of monetising episodic digital engagement in a largely out-of-pocket healthcare system. By 2025, scale without repeatable unit economics had largely ceased to attract fresh capital.
Engagement Reality: Retention, Half-Life, and Human Density
Engagement data from digital therapeutics is now unequivocal. Across mental health and lifestyle programs, ~89 per cent of users disengage after day one, with median retention of just 5.5 days. Even stronger programs see >75 per cent drop-off within weeks, and by 6-12 weeks, active users often fall below 10 per cent. These curves mirror global data and are especially pronounced in self-guided Indian pilots.
Where engagement improves, the effect is measurable. Moderated or blended programs retain ~55 per cent of users at 6 weeks and ~40 per cent at 12 weeks, compared with <30 per cent retention for unmoderated apps. When digital tools are reinforced by clinicians, average engagement extends from ~6 days to ~40 days. The implication is structural: digital therapeutics without human reinforcement function more like content than care.
Outcomes: Incremental Gains, Emerging Signals
Clinical outcomes still justify measured expectations. A review of 41 randomized trials of mobile diabetes programs showed an average 0.49 percentage point reduction in HbA1c versus standard care—a genuine but modest benefit at scale. Some Indian pilots report larger gains, including 1.69 percentage point HbA1c reduction and 2.6 kg weight loss, but these results largely come from small, unpublished cohorts.
That evidence gap is beginning to narrow. Interim findings from an ongoing Indian clinical trial enrolling 880 patients, with outcomes available for 349, show clearer real-world impact. Thirty-day rehospitalisation rates were 0.5 per cent versus 1.3 per cent with usual care, medication adherence at three months reached 90 per cent versus 40 per cent, and blood pressure control improved in 71 per cent versus 55 per cent of patients. Risk factors also improved, including 2.5 kg versus 0.5 kg weight reduction and a 5.1 mg/dl decrease in total cholesterol versus a 15.0 mg/dl increase. While survival outcomes need longer follow-up, these results suggest structured digital cardiac care can deliver benefits beyond symptom tracking.
Hospitals and Evidence-Based Chronic Care Pathways
A key shift in 2024-25 has been the adoption of structured, evidence-based chronic care pathways, particularly within hospitals and emerging insurer programs. Instead of standalone apps, digital tools are being embedded into protocol-driven pathways aligned with clinical guidelines, combining symptom monitoring, medication adherence, lifestyle counselling, and escalation rules.
Telemedicine data explains this shift. India's national telemedicine platform crossed ~360 million cumulative consultations by 2025, with follow-up visits rising from ~23 per cent in 2022 to ~65 per cent by mid-2023. Follow-ups are inherently longitudinal, making them better suited to structured pathways than episodic engagement tools. Hospitals report improved care continuity and reduced outpatient congestion, even as formal outcome deltas continue to be measured.
Insurers are converging on similar logic. Rather than funding generic wellness programs, they increasingly explore chronic-condition management, where even 3–5 per cent reductions in medical costs could justify investment. While outcome-linked contracts remain limited, expectations have clearly shifted from engagement metrics to cost offsets.
Pharma, Therapeutics, and the Limits of Digital Adjuncts
Pharmaceutical use of digital health in India remains focused on chronic therapies such as diabetes, cardiovascular disease, and metabolic disorders, where long-term treatment enables monitoring and adherence. Regulatory recognition of continuous glucose monitoring as mainstream reflects this convergence.
At the same time, evidence linking digital tools to prescription growth or sustained adherence in India remains largely anecdotal. While global studies cite 2–5 per cent prescription uplift, there is still no peer-reviewed Indian data confirming similar effects. In specialty areas like oncology or rare diseases, digital support is largely limited to reminders, with no documented impact on treatment completion or survival.
Post-discharge care shows promise but remains under-documented. International pilots in heart failure and COPD report lower readmissions, while Indian programs are typically small, with hospitals citing 5-10 per cent reductions in 30-day readmissions from internal audits rather than published studies. As a result, pharma and payers increasingly insist on India-specific real-world evidence before scaling.
Insurers, Employers, and the ROI Threshold
By 2025, insurers and large employers sharply reduced spending on generic wellness programs. Corporate data shows <10 per cent of employees remain active in year-long initiatives. Renewals now hinge on sustained engagement—typically 20-30 per cent active users at 3-6 months—and demonstrable cost offsets.
Informal benchmarks suggest digital chronic care programs must deliver ~3-5 per cent medical cost reduction to break even, with expectations that Rs 1 invested should save Rs 3-4 over 2-3 years. Global reference points, such as programs reporting ~$1,169 annual savings per participant, shape expectations but do not replace local validation.
Regulation, Compliance, and Structural Gravity
Regulation has become decisive. Draft guidance on Software as a Medical Device requires software used for diagnosis, monitoring, or treatment to meet medical device standards, extending time-to-market by 6-12 months or more. The Digital Personal Data Protection (DPDP) Act adds further weight, mandating consent, 72-hour breach notification, and stricter governance for large hospitals. Compliance readiness is now as critical as technical capability.
What 2025 Ultimately Reveals
By 2025, Indian digital health has converged on a harder truth. Engagement without structure decays quickly. Outcomes without evidence do not scale. Technology without institutional anchoring remains peripheral. The models gaining acceptance are not the most innovative, but the most disciplined—low-cost, protocol-driven, and evidence-aligned systems embedded into hospital and payer workflows.
Digital therapeutics are now judged by numbers—retention curves, outcome deltas, follow-up ratios, cost offsets, and compliance timelines. That rigour signals the sector's coming of age. As evidence accumulates and care pathways strengthen, India stands poised to move beyond digital health as a set of tools, toward digital care as national infrastructure—capable of improving outcomes at population scale, not just generating engagement at the margins.
This authored article was first published in the BW Healthcare (print), May 18, 2026.
